Dashboard
Manage Tickers

NTRANatera, Inc.

Nasdaq natera.com


$ 96.90 $ 3.26 (3.48 %)    

Friday, 03-May-2024 15:59:57 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 435.98 $ 8.58 (2.01 %)
DIA $ 386.87 $ 4.54 (1.19 %)
SPY $ 511.25 $ 6.26 (1.24 %)
TLT $ 89.88 $ 0.90 (1.01 %)
GLD $ 212.97 $ -0.17 (-0.08 %)
$ 96.98
$ 96.20
$ 0.00 x 0
$ 0.00 x 0
$ 94.98 - $ 97.42
$ 36.90 - $ 98.82
939,653
na
11.15B
$ 1.19
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 02-29-2024 12-31-2023 10-K
2 11-09-2023 09-30-2023 10-Q
3 08-03-2023 06-30-2023 10-Q
4 05-10-2023 03-31-2023 10-Q
5 03-01-2023 12-31-2022 10-K
6 11-09-2022 09-30-2022 10-Q
7 08-05-2022 06-30-2022 10-Q
8 05-06-2022 03-31-2022 10-Q
9 02-25-2022 12-31-2021 10-K
10 11-05-2021 09-30-2021 10-Q
11 08-05-2021 06-30-2021 10-Q
12 05-07-2021 03-31-2021 10-Q
13 02-26-2021 12-31-2020 10-K
14 11-06-2020 09-30-2020 10-Q
15 08-07-2020 06-30-2020 10-Q
16 05-08-2020 03-31-2020 10-Q
17 03-02-2020 12-31-2019 10-K
18 11-08-2019 09-30-2019 10-Q
19 08-09-2019 06-30-2019 10-Q
20 05-10-2019 03-31-2019 10-Q
21 03-15-2019 12-31-2018 10-K
22 11-09-2018 09-30-2018 10-Q
23 08-09-2018 06-30-2018 10-Q
24 05-10-2018 03-31-2018 10-Q
25 03-15-2018 12-31-2017 10-K
26 11-09-2017 09-30-2017 10-Q
27 08-09-2017 06-30-2017 10-Q
28 05-10-2017 03-31-2017 10-Q
29 03-16-2017 12-31-2016 10-K
30 11-14-2016 09-30-2016 10-Q
31 08-11-2016 06-30-2016 10-Q
32 05-13-2016 03-31-2016 10-Q
33 03-24-2016 12-31-2015 10-K
34 11-13-2015 09-30-2015 10-Q
35 08-13-2015 06-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

natera-published-personalized-and-tumor-informed-molecular-residual-disease-test-signatera-to-detect-recurrence-early-in-patients-with-early-stage-breast-cancer-in-jco-precision-oncology
Natera Published Personalized And Tumor-in...
05/03/2024 12:05:37

Expanded EBLIS study with up to 12 years of clinical follow-up across all subtypes of breast cancer

natera-announced-the-launch-of-a-new-cfdna-based-fetal-rhd-test
Natera Announced The Launch Of A New cfDNA...
05/01/2024 11:14:59

neutra-corp-files-to-delay-10-k-annual-report
Neutra Corp. Files To Delay 10-K Annual Re...
04/30/2024 20:41:02

-Bloomberg

looking-into-nateras-recent-short-interest
Looking Into Natera's Recent Short Interest
04/23/2024 18:00:25

natera-announces-significant-milestone-with-200-peer-reviewed-publications-highlighting-nateras-technology-in-the-scientific-literature
Natera Announces Significant Milestone wit...
04/22/2024 12:08:09

Demonstrates commitment to generating real-world clinical evidence to change disease management and improve patient outcomesNat...

goldman-sachs-maintains-buy-on-natera-raises-price-target-to-100
Goldman Sachs Maintains Buy on Natera, Rai...
04/15/2024 14:27:53

Goldman Sachs analyst Matthew Sykes maintains Natera (NASDAQ:NTRA) with a Buy and raises the price target from $90 to $100.

natera-announces-publication-of-largest-prospective-dd-cfdna-study-in-kidney-transplantation
Natera Announces Publication Of Largest Pr...
04/11/2024 12:10:56

ProActive study shows Natera's Prospera Kidney™ test detects rejection five months before biopsyNatera, Inc. (NASDAQ:NTRA),...

craig-hallum-assumes-natera-at-buy-announces-price-target-of-117
Craig-Hallum Assumes Natera at Buy, Announ...
04/08/2024 16:43:23

Craig-Hallum analyst Alexander Nowak assumes Natera (NASDAQ:NTRA) with a Buy rating and announces Price Target of $117.

natera-highlights-new-data-from-2-studies-extending-clinical-validation-of-prospera-heart-dd-cfdna-test-for-heart-transplant-recipients
Natera Highlights New Data From 2 Studies ...
04/08/2024 12:03:28

Prospective, multi-center Trifecta-Heart and DTRT-2 studies demonstrate excellent performance of the Prospera Heart test for de...

cracking-the-code-understanding-analyst-reviews-for-natera
Cracking The Code: Understanding Analyst R...
04/05/2024 21:00:27

looking-into-nateras-recent-short-interest
Looking Into Natera's Recent Short Interest
04/05/2024 15:15:26

bernstein-upgrades-natera-to-outperform-announces-120-price-target
Bernstein Upgrades Natera to Outperform, A...
04/05/2024 12:12:00

Bernstein analyst Eve Burstein upgrades Natera (NASDAQ:NTRA) from Market Perform to Outperform and announces $120 price target.

natera-announces-surveillance-analysis-from-phase-3-imvigor011-trial-in-muscle-invasive-bladder-cancer-data-shows-patients-who-remain-signatera-mrd-negative-after-surgery-may-be-spared-from-adjuvant-treatment-with-100-overall-survival-at-12-months
Natera Announces Surveillance Analysis Fro...
04/05/2024 11:04:35

Overall survival (OS) rates of 100% at 12 months and 98% at 18 months, in patients who remained serially MRD-negative. Disea...

natera-announces-phase-3-randomized-circulate-trial-in-france-evaluating-signatera-in-stage-ii-colorectal-cancer-initial-readout-is-expected-in-2025
Natera Announces Phase 3 Randomized CIRCUL...
03/18/2024 11:10:06

natera-inc-commented-on-the-new-kdigo-guideline-supporting-genetic-testing-for-the-majority-of-ckd-patients-to-establish-cause-of-disease-supports-broader-adoption-of-nateras-renasight-test
Natera, Inc. Commented On The New KDIGO Gu...
03/14/2024 13:53:25

Supports broader adoption of Natera's RenasightTM testNatera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA testing,...

disney-natera-chubb-and-a-major-tech-stock-on-cnbcs-final-trades
Disney, Natera, Chubb And A Major Tech Sto...
03/12/2024 12:43:58

On CNBC’s "Halftime Report Final Trades," Amy Raskin of Chevy Chase Trust said Natera, Inc.

Core News & Articles
CNBC Halftime Report Final Trades: Chubb, ...
03/11/2024 17:00:53

9-health-care-stocks-whale-activity-in-todays-session
9 Health Care Stocks Whale Activity In Tod...
03/08/2024 17:35:29

natera-announces-commercial-coverage-for-prospera-kidney-and-prospera-heart-from-a-top-bcbs-plan
Natera Announces Commercial Coverage For P...
03/07/2024 13:09:47

piper-sandler-maintains-overweight-on-natera-raises-price-target-to-110
Piper Sandler Maintains Overweight on Nate...
03/06/2024 14:32:49

Piper Sandler analyst David Westenberg maintains Natera (NASDAQ:NTRA) with a Overweight and raises the price target from $70...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION